Narinder Nangia, PhD

A Combination of Olanzapine and Samidorphan Has No Clinically Relevant Effect on QT Prolongation Up to Supratherapeutic Doses

Background: ALKS 3831, a combination of olanzapine and samidorphan (OLZ/SAM) in development for schizophrenia, is intended to mitigate olanzapine-associated weight gain. This thorough QT ...

Lisa L. von Moltke , MD, FCPP;

Lei Sun , PhD;

Sergey Yagoda , PhD, MD;

Hongqu Xue , PhD;

Randy Brown , MS;

Narinder Nangia , PhD;

Bhaskar Rege , PhD, BPharm;

Borje Darpo , MD, PhD;

David McDonnell , MD;

11/22/2019

Clinical Evaluation of Abuse Potential of Buprenorphine /Samidorphan (BUP/SAM) Combination

Introduction: Buprenorphine (BUP)/samidorphan (SAM) combination is an opioid system modulator being investigated as adjunctive treatment for major depressive disorder (MDD). The human abu...

Narinder Nangia , PhD;

Arielle Stanford , MD;

Andrew J. Cutler , MD;

Sanjeev Pathak , MD;

Sanjay Mathew , MD;

Michael E. DeBakey ;

Beatrice Setnik , PhD;

03/01/2019